Chi-Med appoints Karen Jean Ferrante as director
Dr. Ferrante has more than 20 years of experience in the pharmaceutical industry.
Dr. Ferrante was the former Chief Medical Officer and Head of Research and Development of Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases.
From September 2007 to July 2013, Dr. Ferrante held senior positions at Millennium Pharmaceuticals, Inc. and its parent company, Takeda Pharmaceutical Company Limited, including Chief Medical Officer and most recently as Oncology Therapeutic Area and Cambridge USA Site Head.
From 1999 to 2007, she held positions of increasing responsibility at Pfizer Inc., with the last position as Vice President, Oncology Development.
Dr. Ferrante began her career in the pharmaceutical industry in 1995 as Associate Director of Clinical Oncology at Bristol-Myers Squibb Company.
For more than a decade prior to that, Dr. Ferrante was at the New England Deaconess Hospital in Boston (Beth Israel Deaconess Medical Center), where she completed her internship and residency in internal medicine followed by her fellowship in hematology and oncology.
Dr. Ferrante is currently a member of the board of directors of Progenics Pharmaceuticals, Inc., and MacroGenics, Inc. She was previously a director of Baxalta Incorporated until it was acquired by Shire Pharmaceuticals in 2016.
She has been an author of a number of papers in the field of oncology, an active participant in academic and professional associations and symposia and holder of several patents.
Dr. Ferrante holds a Bachelor of Science Degree in Chemistry and Biology from Providence College and a Doctor of Medicine from Georgetown University. ■
LATEST MOVES FROM United Kingdom
- Micro Focus appoints Lawton Wehle Fitt as director
- Conviviality appoints Mark Moran as CFO
- James Latham appoints Paula Kerrigan as director
- Charles Stanley Group appoints Marcia Campbell as director
- Arix Bioscience appoints Giles Kerr to board
More inside POST